Clinical Trials Browser

Interventional × alectinib × 30 days × Clear all

NCT03178552 2026-06-05

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04774718 2026-06-04

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

Central Nervous System Neoplasms

NCT06765109 2026-06-02

ALKAZAR

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT02075840 2026-05-29

ALEX

Phase 3 Completed

303 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07001384 2026-05-26

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

Lymphoma, Large-Cell, Anaplastic

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a